Solara Active Pharma Sciences Reports Q1 Results: Consolidated Profit Stands at 16.31 Crores Amid Accumulated Losses
Solara Active Pharma Sciences Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company reported profit of Rs. 16.31 crores on a consolidated basis and Rs. 16.99 crores in the standalone segment, following the Board meeting held on July 23, 2026.The results for the quarter show the Company's performance across both consolidated and standalone entities, with operations focused solely on the Active Pharmaceutical Ingredient (API) sector.
Consolidated Financial Performance Highlights
For the quarter ended June 30, 2026, the Group reported a total income of Rs. 384.29 crores. This was derived from revenue from operations of Rs. 381.60 crores and other income of Rs. 2.69 crores. Total expenses for the quarter amounted to Rs. 367.98 crores, resulting in a profit before tax of Rs. 16.31 crores.The consolidated results include the financial information of the Parent company (Solara Active Pharma Sciences Limited) and its subsidiaries: Shasun USA Inc., Chemsvnth Laboratories Private Limited, and Synthix Global Pharma Solutions Limited.
A summary of the consolidated performance metrics is presented below:
| Particulars | 3 months ended June 30, 2026 (Unaudited) | 3 months ended March 31, 2026 (Refer note 9) | Corresponding 3 months ended June 30, 2025 (Unaudited) | Previous Financial Year ended March 31, 2026 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 381.60 crores | 387.29 crores | 319.15 crores | 368.98 crores |
| Other income | 2.69 crores | 4.69 crores | 0.98 crores | 6.16 crores |
| Total income | 384.29 crores | 391.98 crores | 320.13 crores | 1,375.14 crores |
| Total expenses | 367.98 crores | 383.24 crores | 309.61 crores | 1,376.66 crores |
| Profit/(loss) before exceptional item and tax | 16.31 crores | 8.74 crores | 10.52 crores | (1.52) crores |
Standalone Financial Performance Analysis
On a standalone basis for the quarter, Solara Active Pharma Sciences reported total income of Rs. 383.52 crores for the period ended June 30, 2026. Expenses stood at Rs. 366.53 crores, leading to a profit before tax of Rs. 16.99 crores.The standalone results reflect revenue from operations of Rs. 381.60 crores and other income of Rs. 1.92 crores for the quarter.
Key financial data for the standalone segment:
| Particulars | 3 months ended June 30, 2026 (Unaudited) | Preceding 3 months ended March 31, 2026 | Corresponding 3 months ended in previous year | Previous Financial Year ended |
|---|---|---|---|---|
| Revenue from operations | 381.60 crores | 387.29 crores | 319.15 crores | 1,368.98 crores |
| Other income | 1.92 crores | 4.42 crores | 0.98 crores | 5.89 crores |
| Total income (I+ II) | 383.52 crores | 391.71 crores | 320.13 crores | 1,374.87 crores |
| Total expenses (IV) | 366.53 crores | 382.84 crores | 309.60 crores | 1,376.22 crores |
| Profit/(loss) before exceptional item and tax | 16.99 crores | 8.87 crores | 10.53 crores | (1.35) crores |
Financial Health and Corporate Updates
The company's operations relate exclusively to the Active Pharmaceutical Ingredient (API) segment. The results were reviewed by Deloitte Haskins & Sells LLP, Chartered Accountants.In addition to the operational updates, the Company confirmed that it has raised Rs. 442.73 crores against its rights issue quota of Rs. 449.95 crores. This amount comprises receipts from application money (Rs. 157.48 crores), the first call made on May 6, 2025 (Rs. 155.31 crores), and the final call made on May 7, 2026 (Rs. 129.94 crores).
The management stated that the Board of Directors approved these consolidated financial results on a going concern basis, expressing confidence in the renewal of working capital facilities and expectations of continued cash inflows from operations to meet future obligations.
SOLARA Stock Price Movement
Shares of Solara Active Pharma Sciences Limited are shedding ground in live trading, slipping 5.75% as of 2:40 PM, with the stock currently valued at ₹493.65. The decline comes amid significant volatility, as shares trade down sharply from their day high of ₹529.7 amidst 475,375 shares traded so far this session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.